For research use only. Not for therapeutic Use.
Selective inhibitor of human fatty acid synthase (FAS; Ki value 30 nM) that acts by inhibition the β-ketoacyl reductase activity of the enzyme.
KEYWORDS: GSK837149 | supplier | FAS inhibitor | GSK 837149A | GSK-837149A | CAS [13616-29-0] | Fatty acid synthase | FASN | lipids | beta-ketoacyl reductase | KR | CoA | prostate | ovarian | cancer | carcinoma | obesity
| Catalog Number | I011810 |
| CAS Number | 13616-29-0 |
| Molecular Formula | C23H22N8O5S2 |
| Purity | ≥95% |
| IUPAC Name | 1,3-bis[4-[(4-methylpyrimidin-2-yl)sulfamoyl]phenyl]urea |
| InChI | InChI=1S/C23H22N8O5S2/c1-15-11-13-24-21(26-15)30-37(33,34)19-7-3-17(4-8-19)28-23(32)29-18-5-9-20(10-6-18)38(35,36)31-22-25-14-12-16(2)27-22/h3-14H,1-2H3,(H,24,26,30)(H,25,27,31)(H2,28,29,32) |
| SMILES | CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)S(=O)(=O)NC4=NC=CC(=N4)C |
| Reference | MJ Vázquez et al. Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the beta-ketoacyl reductase reaction. FEBS J. 2008 Apr;275(7):1556-67.
R Flavin et al. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010 Apr;6(4):551-62. |
